BioScience Health Innovations, Inc. (NOTR) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
2722 S WEST TEMPLE SALT LAKE CITY, UT 84115 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 7374 - Computer Processing and Data Preparation and Processing Services (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2025 MRQ | 12/31/2024 | 12/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 663 | 19 | 16 | 2 | 21 | |||
| Cash and cash equivalent | 663 | 19 | 16 | 2 | 21 | |||
| Receivables | 122 | 36 | ||||||
| Inventory, net of allowances, customer advances and progress billings | 58 | 38 | ||||||
| Inventory | 58 | 38 | ||||||
| Prepaid expense | 5 | 4 | ||||||
| Total current assets: | 848 | 93 | 16 | 6 | 21 | |||
| Noncurrent Assets | ||||||||
| Intangible assets, net (including goodwill) | 26 | |||||||
| Intangible assets, net (excluding goodwill) | 26 | |||||||
| Total noncurrent assets: | 26 | |||||||
| TOTAL ASSETS: | 874 | 93 | 16 | 6 | 21 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 14 | 9 | 2 | 0 | 7 | |||
| Interest and dividends payable | ✕ | ✕ | ✕ | ✕ | 0 | |||
| Accounts payable | 8 | 8 | 2 | 7 | ||||
| Accrued liabilities | 6 | 1 | ||||||
| Deferred revenue | 24 | 4 | ||||||
| Debt | 9 | |||||||
| Due to related parties | ✕ | ✕ | ✕ | 3 | 1 | |||
| Total current liabilities: | 39 | 13 | 2 | 12 | 8 | |||
| Noncurrent Liabilities | ||||||||
| Other undisclosed liabilities | 87 | 7 | ||||||
| Total liabilities: | 39 | 100 | 2 | 19 | 8 | |||
| Equity | ||||||||
| Equity, attributable to parent | 835 | (7) | 14 | (13) | 13 | |||
| Preferred stock | 0 | 0 | 0 | |||||
| Common stock | 4 | 4 | 1 | 1 | 1 | |||
| Additional paid in capital | 1,172 | 417 | 131 | 21 | 21 | |||
| Retained earnings (accumulated deficit) | (341) | (428) | (117) | (34) | (9) | |||
| Total equity: | 835 | (7) | 14 | (13) | 13 | |||
| TOTAL LIABILITIES AND EQUITY: | 874 | 93 | 16 | 6 | 21 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2025 TTM | 12/31/2024 | 12/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 1,845 | 598 | |||||
| Cost of revenue (Cost of Product and Service Sold) | (536) | (113) | |||||
| Gross profit: | 1,309 | 484 | |||||
| Operating expenses | (1,222) | (736) | (92) | (26) | (8) | ||
| Operating income (loss): | 87 | (252) | (92) | (26) | (8) | ||
| Nonoperating income (Other Nonoperating income) | 9 | ||||||
| Interest and debt expense | 9 | (0) | |||||
| Income (loss) from continuing operations before equity method investments, income taxes: | 87 | (252) | (74) | (26) | (8) | ||
| Other undisclosed loss from continuing operations before income taxes | (9) | ||||||
| Income (loss) from continuing operations: | 87 | (252) | (83) | (26) | (8) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (83) | (26) | (8) | |
| Net income (loss): | 87 | (252) | (83) | (26) | (8) | ||
| Other undisclosed net income attributable to parent | 0 | ||||||
| Net income (loss) available to common stockholders, diluted: | 87 | (252) | (83) | (26) | (8) | ||
Comprehensive Income ($ in thousands)
| 3/31/2025 TTM | 12/31/2024 | 12/31/2023 | 8/31/2022 | 8/31/2021 | 8/31/2020 | ||
|---|---|---|---|---|---|---|---|
| Net income (loss): | 87 | (252) | (83) | (26) | (8) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 87 | (252) | (83) | (26) | (8) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.